CN102216285B - 四取代的哒嗪hedgehog途径拮抗剂 - Google Patents

四取代的哒嗪hedgehog途径拮抗剂 Download PDF

Info

Publication number
CN102216285B
CN102216285B CN200980145554.8A CN200980145554A CN102216285B CN 102216285 B CN102216285 B CN 102216285B CN 200980145554 A CN200980145554 A CN 200980145554A CN 102216285 B CN102216285 B CN 102216285B
Authority
CN
China
Prior art keywords
compound
cancer
pharmaceutically acceptable
methyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980145554.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102216285A (zh
Inventor
J·A·巴斯蒂安
J·M·克雷
J·D·科恩
P·A·希普斯金德
K·L·洛伯
D·J·萨尔
T·威尔森(尼高桑)
M·L·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102216285A publication Critical patent/CN102216285A/zh
Application granted granted Critical
Publication of CN102216285B publication Critical patent/CN102216285B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200980145554.8A 2008-11-17 2009-11-05 四取代的哒嗪hedgehog途径拮抗剂 Expired - Fee Related CN102216285B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11533208P 2008-11-17 2008-11-17
US61/115,332 2008-11-17
PCT/US2009/063370 WO2010056588A1 (en) 2008-11-17 2009-11-05 Tetrasubstituted pyridazine hedgehog pathway antagonists

Publications (2)

Publication Number Publication Date
CN102216285A CN102216285A (zh) 2011-10-12
CN102216285B true CN102216285B (zh) 2014-08-13

Family

ID=41722877

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980145554.8A Expired - Fee Related CN102216285B (zh) 2008-11-17 2009-11-05 四取代的哒嗪hedgehog途径拮抗剂

Country Status (18)

Country Link
US (1) US8507490B2 (https=)
EP (1) EP2358698B1 (https=)
JP (1) JP5518887B2 (https=)
KR (1) KR101342184B1 (https=)
CN (1) CN102216285B (https=)
AU (1) AU2009314349B2 (https=)
BR (1) BRPI0921782A2 (https=)
CA (1) CA2743483C (https=)
CY (1) CY1113377T1 (https=)
DK (1) DK2358698T3 (https=)
EA (1) EA017386B1 (https=)
ES (1) ES2392759T3 (https=)
HR (1) HRP20120762T1 (https=)
MX (1) MX2011005177A (https=)
PL (1) PL2358698T3 (https=)
PT (1) PT2358698E (https=)
SI (1) SI2358698T1 (https=)
WO (1) WO2010056588A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714872A2 (pt) * 2006-07-17 2013-03-19 Syngenta Participations Ag derivados de piridazina
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
EP2364185B1 (en) 2008-11-03 2013-05-22 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105130980B (zh) * 2015-09-09 2018-05-22 沈阳药科大学 N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
CN110208424A (zh) * 2019-06-28 2019-09-06 江苏恒生检测有限公司 一种农药氟啶虫酰胺中含有杂质的分析方法
WO2021071981A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
US20250333397A1 (en) * 2021-08-30 2025-10-30 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110611A1 (en) * 2007-03-15 2008-09-18 Novartis Ag Organic compounds and their uses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
ATE203534T1 (de) 1996-01-15 2001-08-15 Janssen Pharmaceutica Nv Angiogenesis hemmende pyridazinamine
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
IL138645A0 (en) 1998-04-09 2001-10-31 Univ Johns Hopkins Med Use of steroidal alkaloid derivatives as inhibitors of hedghog signalling pathways
CA2376210A1 (en) 1999-06-08 2000-12-14 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
DE60322869D1 (de) 2002-04-22 2008-09-25 Univ Johns Hopkins Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
DK1789390T3 (da) 2004-09-02 2012-02-27 Genentech Inc Pyridyl-inhibitorer af hedgehog-signalering
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP2364185B1 (en) 2008-11-03 2013-05-22 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110611A1 (en) * 2007-03-15 2008-09-18 Novartis Ag Organic compounds and their uses

Also Published As

Publication number Publication date
EA201170699A1 (ru) 2011-12-30
ES2392759T3 (es) 2012-12-13
US8507490B2 (en) 2013-08-13
EA017386B1 (ru) 2012-12-28
AU2009314349A1 (en) 2010-05-20
CA2743483A1 (en) 2010-05-20
PT2358698E (pt) 2012-10-24
JP2012509263A (ja) 2012-04-19
CA2743483C (en) 2014-03-11
SI2358698T1 (sl) 2012-11-30
PL2358698T3 (pl) 2013-01-31
AU2009314349B2 (en) 2013-04-18
DK2358698T3 (da) 2012-10-08
US20110263602A1 (en) 2011-10-27
KR20110070920A (ko) 2011-06-24
EP2358698A1 (en) 2011-08-24
CN102216285A (zh) 2011-10-12
KR101342184B1 (ko) 2013-12-19
JP5518887B2 (ja) 2014-06-11
HRP20120762T1 (hr) 2012-10-31
CY1113377T1 (el) 2016-06-22
MX2011005177A (es) 2011-05-30
BRPI0921782A2 (pt) 2019-09-24
WO2010056588A1 (en) 2010-05-20
EP2358698B1 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
CN102216285B (zh) 四取代的哒嗪hedgehog途径拮抗剂
CN102459233B (zh) 二取代的酞嗪hedgehog途径拮抗剂
KR101260116B1 (ko) 이치환된 프탈라진 헤지호그 경로 길항제
CN102216292B (zh) 四取代的哒嗪hedgehog途径拮抗剂
MX2011004683A (es) Antagonistas de la via hedgehog de ftalazina disustituida.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140813

Termination date: 20151105

EXPY Termination of patent right or utility model